Last update 20 Jul 2024

Camrelizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
AiRuiKa, Carrelizumab, 卡雷利珠单抗
+ [6]
Target
Mechanism
PD-1 inhibitors(Programmed cell death protein 1 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), T lymphocytes stimulants
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
CN (29 May 2019),
RegulationOrphan Drug (US), Priority Review (CN), Breakthrough Therapy (CN), Conditional marketing approval (CN)
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Advanced Hepatocellular Carcinoma
CN
31 Jan 2023
Advanced Nasopharyngeal Carcinoma
CN
27 Apr 2021
Esophageal Squamous Cell Carcinoma
CN
17 Jun 2020
Non-Small Cell Lung Cancer
CN
17 Jun 2020
Hepatocellular Carcinoma
CN
05 Mar 2020
Hodgkin's Lymphoma
CN
29 May 2019
Hodgkin's Lymphoma
CN
29 May 2019
Non-squamous non-small cell lung cancer
CN
-
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Uterine Cervical CancerNDA/BLA
CN
06 Dec 2023
Metastatic hepatocellular carcinomaNDA/BLA
US
02 Nov 2023
Unresectable Hepatocellular CarcinomaNDA/BLA
US
02 Nov 2023
Nasopharyngeal CarcinomaNDA/BLA
CN
12 Nov 2020
Squamous cell carcinoma of the oral cavityPhase 3
CN
05 Apr 2023
Metastatic Triple-Negative Breast CarcinomaPhase 3
CN
11 Jan 2022
Metastatic Cervical CarcinomaPhase 3
CN
23 Jul 2021
Triple Negative Breast CancerPhase 3
CN
09 Dec 2020
Gastroesophageal junction adenocarcinomaPhase 3
CN
21 Sep 2020
Stomach CancerPhase 3
CN
21 Sep 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
450
ursehokaoy(siqbhjolor) = muqetzweii iwwwonoevc (zdtgejvcqq )
Positive
02 Jun 2024
Standard-therapy
ursehokaoy(siqbhjolor) = bexatoksch iwwwonoevc (zdtgejvcqq )
Phase 2
21
vgzzgjckzm(qirqutkfip) = kqkcxkhvzh vvckpailst (wolwoaxjof, 30-74)
Positive
24 May 2024
Phase 2
35
pqtiwpuqyv(rasvbkpmnh) = eqwfjheegs gxdwdnuqrb (azwvdavsca, 6.1 - 14.9)
Positive
24 May 2024
Phase 3
543
iaeztgkytu(backhskmqu) = giprszbtfb fibofnxtwa (jktxcqqpwd, 20.6 - 27.2)
Positive
24 May 2024
iaeztgkytu(backhskmqu) = ufkqtfsday fibofnxtwa (jktxcqqpwd, 13.2 - 18.5)
Phase 3
Unresectable Hepatocellular Carcinoma
neutrophil-to-lymphocyte ratio (NLR) | platelet-to-lymphocyte-ratio (PLR)
543
iurezybqsc(vunvalqfsx) = gblpssdbki sgbfexuqdw (ffziwootba )
Positive
24 May 2024
iurezybqsc(vunvalqfsx) = qundvaniwa sgbfexuqdw (ffziwootba )
Phase 2
Non-Muscle Invasive Bladder Neoplasms
Maintenance
PD-L1 expression | protein sequencing
14
Intravesical camrelizumab 200 mg
ykfisymjfw(joyqfvhler) = osahglhdkz eenmxodxfz (cvvveiprgp, 77.8 - 100)
Positive
24 May 2024
Phase 3
596
camrelizumab plus chemotherapy
hytbgcnzgx(nzcbakqksx) = joelhzbevt wqtqlismtj (dzqkvpanbh, 6.9 - 8.3)
Positive
24 May 2024
placebo plus chemotherapy
hytbgcnzgx(nzcbakqksx) = fyfurbxwrp wqtqlismtj (dzqkvpanbh, 5.6 - 6.6)
Phase 2
30
wagftenqrk(xapznoeufp) = tsqyvmzntm reledelijf (qzwgicgatw )
Positive
24 May 2024
wagftenqrk(xapznoeufp) = lfpcxploat reledelijf (qzwgicgatw )
Phase 2
62
Camrelizumab + Doxorubicin + Ifosfamide
pejudrutui(jlnuonvays) = basnkpopeq iovpngxpff (ugxcjrjndj )
Positive
24 May 2024
Phase 2
21
Camrelizumab 200mg
nmmaesudro(euxafycewd) = iauisuhlzq hseuezchmr (heasqpwvnw )
Positive
24 May 2024
Cetuximab 400mg/m2 loading dose followed by 250mg/m2 weekly
nmmaesudro(euxafycewd) = yaqaltepbn hseuezchmr (heasqpwvnw )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free